(ICHN) iShares MSCI China USD - Ratings and Ratios
Chinese, stocks, equities
Description: ICHN iShares MSCI China USD
The iShares MSCI China UCITS ETF USD Acc (ICHN) is an exchange-traded fund that tracks the Morningstar China TME NR USD Index, providing investors with exposure to the Chinese equity market. As a Netherlands-originated ETF, it is designed to cater to the investment needs of those seeking to tap into Chinas growth potential.
From a technical analysis perspective, the ETFs price action indicates a bullish trend, with its short-term and long-term moving averages (SMA20: 5.42, SMA50: 5.26, SMA200: 4.93) suggesting a gradual upward momentum. The Average True Range (ATR: 0.08 = 1.50%) implies a relatively stable volatility profile. Considering the current price (5.44) is near the 52-week high (5.82) and significantly above the 52-week low (3.94), it indicates a strong recovery and potential for further growth.
Fundamentally, the ETFs Assets Under Management (AUM: 3962.53M USD) signify a substantial investor interest and confidence in the Chinese equity market. As a China Equity ETF, it is likely to be heavily influenced by the overall performance of the Chinese economy, including factors such as GDP growth, trade policies, and regulatory changes.
Combining both technical and fundamental insights, a forecast for ICHN could be constructed. Given the ETFs current technical setup and the significant AUM, a potential target price could be estimated. If the ETF maintains its upward momentum and breaks through the 52-week high (5.82), it may aim for new highs, potentially reaching 6.20-6.50 in the next 6-12 months, driven by continued Chinese economic growth and investor appetite for China equities. However, a decline below the SMA50 (5.26) could signal a reversal, warranting a reassessment of the investment thesis.
Additional Sources for ICHN ETF
ICHN ETF Overview
Market Cap in USD | 3,963m |
Category | China Equity |
TER | 0.28% |
IPO / Inception | 2019-06-20 |
ICHN ETF Ratings
Growth Rating | -10.3 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | 17.7 |
Analysts | - |
Fair Price Momentum | 5.45 USD |
Fair Price DCF | - |
ICHN Dividends
Currently no dividends paidICHN Growth Ratios
Growth Correlation 3m | 83.2% |
Growth Correlation 12m | 80.2% |
Growth Correlation 5y | -63.1% |
CAGR 5y | -3.43% |
CAGR/Max DD 5y | -0.05 |
Sharpe Ratio 12m | -0.17 |
Alpha | 22.65 |
Beta | 0.585 |
Volatility | 22.91% |
Current Volume | 88.3k |
Average Volume 20d | 195.5k |
Stop Loss | 5.4 (-2.9%) |
As of July 09, 2025, the stock is trading at USD 5.56 with a total of 88,257 shares traded.
Over the past week, the price has changed by -0.03%, over one month by +0.51%, over three months by +19.05% and over the past year by +34.78%.
Neither. Based on ValueRay´s Analyses, iShares MSCI China USD is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -10.34 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ICHN is around 5.45 USD . This means that ICHN is currently overvalued and has a potential downside of -1.98%.
iShares MSCI China USD has no consensus analysts rating.
According to our own proprietary Forecast Model, ICHN iShares MSCI China USD will be worth about 6.2 in July 2026. The stock is currently trading at 5.56. This means that the stock has a potential upside of +10.97%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 6.2 | 11% |